Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

ChemoCentryx to Participate in Two Upcoming Investor Conferences

Epizyme

Hutchison China MediTech Ltd.

Magenta Therapeutics Inc

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Big Pharma Is Going Holiday Shopping. Who's Next?

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?

SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology (ACR) Convergence 2021, taking place November 2-7, 2021 and November 3-9, 2021, respectively.

Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions.

ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has skyrocketed with a 104% rise over the last month. This can be attributed to an unexpected U.S. FDA approval of Tavneos - an oral drug

What's Next For ChemoCentryx Stock After Over A 100% Rise In A Month?

Axsome Therapeutics

Ocular Therapeutix

These stocks are expected to put up big gains in a short amount of time.

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

The stock surged after obtaining FDA approval for avacopan.

Is It Too Late to Buy ChemoCentryx Stock?

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis), in combination with standard therapy. TAVNEOS™ is manufactured by California-based ChemoCentryx, Inc., a biopharma company focus

Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-Associated Vasculitis

BioCryst Pharmaceuticals

These two small drugmakers are poised for a long-winded growth spurt.

2 Super-Charged Growth Stocks to Buy Now

There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).

BZ Chart Of The Day: ChemoCentryx

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 9% during intraday trading today. This is why it happened.

CCXI Stock: Why It Increased Today

Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product

ChemoCentryx Appoints Rita I. Jain, M.D.

Investors are excited about the biotech's game-changing new drug.

Why ChemoCentryx Stock Skyrocketed Today

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively blocks the effects of C5a through the C5a receptor.

Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?

The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval.

ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis

ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 88% during intraday trading today. This is why it happened.

CCXI Stock Price: Why It Increased By Over 88% Today

CCXI stock is making its investors very happy this morning with some huge gains. It's receiving FDA approval for a rare disease treatment.

CCXI Stock: The Big FDA News That Has ChemoCentryx Shares Skyrocketing 60%

ChemoCentryx Inc (NASDAQ: CCXI) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group.

Here's why ChemoCentryx is up 50% on Friday morning

ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The company said this is the first new drug to treat the rare autoimmune disease in a decade.

News for Chemocentryx Stock (CCXI)